Immune-Onc Therapeutics Raises $73 Million Series B1/B2 Financing, CEC Capital Group Served as Exclusive Financial Advisor

Immune-Onc is a clinical-stage biopharmaceutical company dedicated to developing novel cancer immunotherapies targeting a new myeloid cell immune checkpoint for cancer patients worldwide. The company recently completed an approximately $73 million B1/B2 round financing. The funding was led by Oceanpine Capital, with participation from prominent domestic funds including Yinglian Health Fund, South China Venture Capital, Qianzhan Investment Management, Triwise International Capital, YC Capital, BOCOM International, Tao Capital, as well as well-known international funds like Octagon Capital and Sphera Healthcare, and strategic investors such as WuXi Biologics. Existing shareholders like Northern Light Venture Capital and Vivo Capital also continued their support. To date, Immune-Onc has raised a total of over $110 million. The funds raised in this round will be mainly used to advance and expand the development of its pioneering drug pipeline globally and support the company's operations in both the United States and China.

CEC Capital Group served as the exclusive financial advisor in this transaction for Immune-Onc.